.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,691,880

« Back to Dashboard
Patent 7,691,880 protects METHYLIN and is included in one NDA. There has been one Paragraph IV challenge on Methylin. There are three tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has ten patent family members in nine countries.

Summary for Patent: 7,691,880

Title:Methylphenidate solution and associated methods of administration and production
Abstract:A methylphenidate solution and associated methods of administration and production, which includes methylphenidate and at least one organic acid dissolved in a solvent system, where the solvent system includes at least one non-aqueous solvent. The solvent system may include water. The non-aqueous solvent can include, but is not limited to polyols and glycols and associated mixtures thereof. Pharmaceutical additives such as flavorings, colorants, buffers, preservatives and mixtures thereof may be optionally added to the methylphenidate solution.
Inventor(s): Herman; Clifford J. (St. Louis, MO)
Assignee: Mallinckrodt Inc. (Hazelwood, MO)
Application Number:10/554,133
Patent Claim Types:
see list of patent claims
Formulation; Compound;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 3rd percentile
Forward Citations: 13th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Mallinckrodt
METHYLIN
methylphenidate hydrochloride
SOLUTION;ORAL021419-001Dec 19, 2002RXYes7,691,880► subscribeY
Mallinckrodt
METHYLIN
methylphenidate hydrochloride
SOLUTION;ORAL021419-002Dec 19, 2002RXYes7,691,880► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,691,880

PCT Information
PCT FiledOctober 07, 2004PCT Application Number:PCT/US2004/033268
PCT Publication Date:April 21, 2005PCT Publication Number: WO2005/035000

International Patent Family for Patent: 7,691,880

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan4959335► subscribe
Japan2007508313► subscribe
Spain2373042► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc